OmniAb's Q2 Revenue Tripled to $13.4M-Now Investors Need Proof It's Not Just a Milestone Pop

Milestone-driven Q2 revenue nearly tripled, raising the bar for durability

OmniAb reported Q2 revenue of $13.4 million, up from $3.9 million a year earlier, and raised its full-year 2026 revenue and cash outlook. That is strong news, but it does not fully answer the harder question: is this a durable operating model, or a quarter helped by uneven payment timing?

Management said the increase was driven primarily by milestone revenue. That matters because milestone income can be lumpy. The counterpoint is that other parts of the business also improved: service revenue increased and xPloration revenue increased. The key issue going forward is whether those steadier revenue streams grow fast enough to support the raised outlook.

Partner growth was modest, but it still points to wider adoption

Active partners and programs kept expanding

OmniAb reported 110 active partners, up from 107 active partners, and 425 active programs, up from 407. The gains are not huge, but they do suggest the partner base is continuing to widen rather than stall.

A larger program base matters because it creates more opportunities for future milestones, services, and, over time, royalties. It also reduces dependence on any single deal closing in one quarter. That view is reinforced by the company's earlier quarter announcements with Argenx and Rosa Therapeutics, which show that partner demand is still coming in.

Clinical progress and platform utility matter more than the headline quarter

The more important evidence is whether OmniAb's platforms are helping partners move assets forward. Management highlighted that two programs (rimantomib and persentabartosentican) jumped from Phase 1 directly into Phase 3 during Q2. For biotech partners, that kind of clinical progression is a useful sign that the technology is delivering real value.

OmniAb is also seeing strong adoption of its Omni Ultra technology. When that traction is combined with rising service and xPloration activity, it suggests customers are not just licensing a brand name; they are using the company's tools and support offerings. The quarter also included the sale of two instruments in Q2, which points to ongoing product usage through the xPloration program.

Cost control and cash give OmniAb time to prove the model

This was not a quarter that looked like management was chasing growth at any cost. OmniAb said Q2 2026 total costs and operating expenses were $20.1 million, flat year-over-year, while cash costs and operating expenses (non-GAAP) for Q2 2026 were $13.3 million. The company also said cash position grew to $52 million in Q2 and improved its net loss to $5.9 million in Q2 2026, compared with a net loss of $15.9 million in the year-ago period.

That gives OmniAb room to keep building the partner pipeline without immediate balance-sheet pressure. The raised outlook is constructive, but the cash position is best viewed as time to deliver proof, not as proof itself.

What investors need to see after the guidance raise

OmniAb now expects full-year 2026 revenue of $32 million to $36 million and said year-end cash projected at $37–$41 million. That updated outlook is encouraging, but the next rerating likely requires more than another strong quarter. Investors need evidence that higher revenue is being supported by broader customer usage across the base of 110 active partners and 425 active programs, not just by another clustered milestone payment.

What to watch next

• October Investor and Analyst Day: Management said it look[s] forward to providing business updates and technology highlights and plans at our October Investor and Analyst Day. That should be a useful window into whether partner progress is broadening.
• Revenue mix: Watch whether service revenue increased and xPloration revenue increased again in coming quarters. Those are better indicators of repeatable demand than milestone revenue alone.
• Royalties: The company said Royalties are expected to become a growing revenue stream as partner programs advance. That may be early, but investors should look for signs that the base of 110 active partners and 425 active programs is eventually feeding into more recurring revenue.
• Partner momentum: If partner and program growth flattens after reaching 110 partners, the case for durable adoption will be harder to make.

For now, the quarter looks constructive rather than conclusive. The milestone-driven rebound improved the story, but sustained revenue quality will depend on whether OmniAb can turn a wider partner base into steadier services, xPloration activity, and eventually royalties.